ALAN H. AUERBACH - 18 Feb 2026 Form 4 Insider Report for PUMA BIOTECHNOLOGY, INC. (PBYI)

Role
President and CEO, Director, 10%+ Owner
Signature
/s/ Gordon Esplin as attorney-in-fact for Alan H. Auerbach
Issuer symbol
PBYI
Transactions as of
18 Feb 2026
Net transactions value
$0
Form type
4
Filing time
20 Feb 2026, 20:29:13 UTC
Previous filing
08 Jan 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
AUERBACH ALAN H President and CEO, Director, 10%+ Owner C/O PUMA BIOTECHNOLOGY, INC., 10880 WILSHIRE BLVD., SUITE 1700, LOS ANGELES /s/ Gordon Esplin as attorney-in-fact for Alan H. Auerbach 20 Feb 2026 0001358285

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PBYI Common Stock Award $0 +159,778 +2.2% $0.000000 7,305,729 18 Feb 2026 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PBYI Stock Option (Right to Buy) Award $0 +227,474 $0.000000 227,474 18 Feb 2026 Common Stock 227,474 $6.68 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the grant of Restricted Stock Units ('RSUs"). Subject to the Reporting Person's continued status as an Employee of the Company, the RSUs shall vest with respect to one-fourth (1/4th) of the RSUs on each of July 1, 2026, January 1, 2027, July 1, 2027 and January 1, 2028, subject to acceleration in certain events.
F2 Subject to the Reporting Person's continued status as an Employee of the Company, the Options shall vest and become exercisable with respect to one-fourth (1/4th) of the shares of Common Stock subject thereto on each of July 1, 2026, January 1, 2027, July 1, 2027 and January 1, 2028, subject to acceleration in certain events.